Skip to main content
. Author manuscript; available in PMC: 2025 Jan 1.
Published in final edited form as: J Pathol. 2023 Oct 18;262(1):105–120. doi: 10.1002/path.6216

FIGURE 1. Validation of a monoclonal HOXB13 antibody.

FIGURE 1.

A. Western blot of lysates from prostate cancer cell lines (LNCaP, DU145) and tissues from prostate cancer patient-derived xenografts (LuCaP 35, LuCaP 78) probed with HOXB13 antibody (clone D7N8O) show a single band at the predicted molecular weight of HOXB13 (34 kDa). B. IHC on formalin fixed paraffin embedded cell lines with known HOXB13 expression define the specificity of clone D7N8O. LNCaP and LuCaP35 show strong reactivity; DU145 and H660 are negative for HOXB13. Lentiviral over-expression (HOXB13 OE) results in robust labeling of HOXB13 in DU145HOXB13OE and H660HOXB13OE cells. C. HOXB13 expression in developing mouse embryo (E17.5). HOXB13 labeling is restricted to the urogenital sinus (UGS), distal colon/rectum and tail, recapitulating the expression pattern described by reporter and RNA in situ labeling previously shown [6] . Scale bars denote 50 μm, if not otherwise specified.